Boditech Med

• HbA1c, insulin, and C-peptide testing available on a single platform within 12 minutes
• A paradigm shift in POC diabetes diagnostics: assessing underlying causes, not just blood sugar levels
• Sustained growth trajectory fueling accelerated global expansion

Seoul, South Korea – September 19, 2025 – Boditech Med, a leading provider of point-of-care diagnostics, showcased its groundbreaking diabetes diagnostic solutions at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD 2025), held in Vienna, Austria from September 16–19. The event attracted over 15,000 diabetes experts, clinicians, and industry professionals from around the world.

At its booth, Boditech Med highlighted the unique value of its platform, which enables rapid measurement of HbA1c, insulin, and C-peptide directly from whole blood in as little as 12 minutes. Traditionally, insulin and C-peptide testing has required large laboratory-based systems with limited accessibility. Boditech Med’s solution allows clinicians to simultaneously evaluate insulin resistance through indices such as HOMA-IR, as well as assess β-cell function and insulin secretion capacity. This represents a shift beyond standard blood glucose monitoring—offering a more comprehensive approach to diagnosing and managing diabetes.

The company reported strong engagement during the exhibition, with approximately 300 endocrinologists, laboratory directors, and diabetes specialists from over 30 countries visiting its booth. Particular interest was shown in the insulin/C-peptide panel and insulin resistance evaluation solution, underscoring market demand for rapid point-of-care testing. The demonstration further enhanced Boditech Med’s brand recognition among global diabetes experts.

Boditech Med’s diabetes product portfolio has shown sustained high growth. Revenue from diabetes-related products grew from KRW 4.4 billion in 2019 to over KRW 13 billion in 2024, recording a compound annual growth rate (CAGR) of more than 24%. The company expects growth of over 25% in 2025. While HbA1c products have historically led sales, the company anticipates significant contributions from insulin and C-peptide diagnostics going f orward, given their clinical utility in reflecting endogenous insulin secretion and β-cell function.

Eui-yeol Choi, CEO of Boditech Med, stated:

“EASD 2025 provided an important opportunity to introduce the new value of ‘diabetes diagnostics beyond glucose’ to a global audience. We will continue to deliver innovative solutions that provide tangible benefits to clinicians and patients, while accelerating our global expansion in the diabetes diagnostics market.”

• Q2 2025 revenue of $30.74M (KRW 41.5B), up 14.5% YoY
• Operating profit of $6.81M (KRW 9.2B), up 13.9% QoQ; operating margin at 22.2%
• Double-digit growth in MENA and Latin America; notable rebound in Europe

Gangwon-do, Korea – August 8, 2025 – Boditech Med Inc. (CEO Eui-Yul Choi), a global point-of-care diagnostics company, today announced its preliminary consolidated financial results for the second quarter of 2025, reporting revenue of $30.74 million (KRW 41.5 billion) and operating profit of $6.81 million (KRW 9.2 billion). This represents a 14.5% year-on-year increase in revenue and a 0.7% year-on-year decrease in operating profit. Compared to the previous quarter, revenue grew by 6.2% and operating profit rose by 13.9%, with the operating margin improving to 22.2% from 20.7% in Q1.

Growth in Q2 was driven by strong performance across major global markets. The Middle East and North Africa (MENA) region posted a 29.3% increase in revenue, accounting for 25.5% of total sales and serving as a key growth engine. Latin America achieved rapid growth with a 38.6% increase, while Europe recorded a 5.9% increase, reflecting a clear recovery trend.

As of Q2 2025, revenue distribution by region was: MENA 25.5%, Europe 23.0%, Asia 18.6%, Latin America 14.3%, Africa 8.1%, and domestic (Korea) 7.3%, underscoring the company’s expanding global diversification.

By product category, non-communicable disease diagnostics showed notable growth. Cardiovascular products grew by 16.1%, diabetes diagnostics by 13.2%, and other disease categories by 49.5%, the highest growth rate. Hormone and infectious disease diagnostics remained steady, while cancer-related diagnostics maintained stable growth.

Boditech Med installed over 7,300 diagnostic instruments in the first half of 2025, equivalent to around 70% of the total installations in 2024 (10,552 units). In Q2 alone, 4,111 units were newly installed, including 2,623 units of its flagship AFIAS and ichroma™ series. While installation volumes surged during the pandemic and temporarily declined post-endemic, a robust recovery began in 2023, and 2025 is projected to mark a record-high in new installations.

CEO Eui-Yul Choi commented, “Our Q2 performance demonstrates the success of Boditech Med’s global market diversification and expanded product portfolio. The focus on high value-added products significantly contributed to improved profitability.” He added, “In the second half, we will intensify efforts to expand into new business areas such as clinical chemistry, hematology, and veterinary diagnostics, while strengthening quality competitiveness to penetrate developed markets.”

• Highlights include AFIAS automated immunoassay platform and key products like IGRA-TB and PENKID
• Launch of new veterinary POCT solutions including AFIAS-VET, VETCHROMA 3, UROCHROMA, and VETCHEMIS
• Strengthening market re-entry in North and South America through global partnerships and innovation

Boditech Med, a leading provider of point-of-care diagnostics, announced its participation in ADLM 2025 (Association for Diagnostics & Laboratory Medicine), held from July 29 to 31 in Chicago, USA.

As the largest diagnostics exhibition in North America, ADLM 2025 hosts more than 20,000 professionals and over 800 companies worldwide. This year’s event features more than 850 booths, along with keynote lectures and workshops addressing key healthcare issues such as AI integration, misinformation in medicine, genomics-based diagnostics, and environmental health impacts.

At the exhibition, Boditech Med is unveiling its AFIAS automated immunoassay platform alongside a comprehensive portfolio of innovative diagnostic solutions. Key highlights include:

• AFIAS IGRA-TB for rapid detection of latent tuberculosis

• PENKID for early prediction and monitoring of acute kidney injury

• TDM, HOMA-IR, and Vitamin D diagnostic kits for endocrine and metabolic assessments

In addition, the company is introducing its latest veterinary diagnostic lineup.

• AFIAS-VET and VETCHROMA 3 support immunoassays for animal diagnostics with automated and manual options to meet diverse on-site testing needs.

• UROCHROMA provides rapid urine analysis, and VETCHEMIS enables blood chemistry testing using whole blood samples—expanding the potential for point-of-care use in veterinary settings.

Through its presence at ADLM 2025, Boditech Med aims to accelerate global market expansion, with a renewed focus on reestablishing its footprint across North and South America. While sales in the Americas saw exceptional growth during the pandemic followed by a period of adjustment, the company is positioning 2025 as a turning point for renewed growth, backed by a strong sales network and expanded partnerships.

Eui-yeol Choi, CEO of Boditech Med, stated:

“ADLM 2025 presents a key opportunity to introduce our cutting-edge diagnostic technologies to the North American and Latin American markets. We are also unveiling our new veterinary diagnostic solutions to broaden our global reach.”

He added, “To further strengthen our regional partnerships, we are hosting the 3rd Latin America Distributor Conference on the eve of the exhibition.”